A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q Syndrome
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of basmisanil
treatment in children with Dup15q syndrome aged 2 to 11 years. The study will test the
hypothesis that modulation of a GABAA receptor subtype can address excessive receptor
function and positively impact core neurodevelopmental disease features in children with
Dup15q syndrome.